Macrophages, which are abundant in the tumour microenvironment, enhance malignancy 1 . At metastatic sites, a distinct population of metastasis-associated macrophages promotes the extravasation, seeding and persistent growth of tumour cells 2 . Here we define the origin of these macrophages by showing that Gr1-positive inflammatory monocytes are preferentially recruited to pulmonary metastases but not to primary mammary tumours in mice. This process also occurs for human inflammatory monocytes in pulmonary metastases of human breast cancer cells. The recruitment of these inflammatory monocytes, which express CCR2 (the receptor for chemokine CCL2), as well as the subsequent recruitment of metastasis-associated macrophages and their interaction with metastasizing tumour cells, is dependent on CCL2 synthesized by both the tumour and the stroma. Inhibition of CCL2-CCR2 signalling blocks the recruitment of inflammatory monocytes, inhibits metastasis in vivo and prolongs the survival of tumour-bearing mice. Depletion of tumour-cell-derived CCL2 also inhibits metastatic seeding. Inflammatory monocytes promote the extravasation of tumour cells in a process that requires monocytederived vascular endothelial growth factor. CCL2 expression and macrophage infiltration are correlated with poor prognosis and metastatic disease in human breast cancer 3-6 . Our data provide the mechanistic link between these two clinical associations and indicate new therapeutic targets for treating metastatic breast cancer.
Macrophages, which are abundant in the tumour microenvironment, enhance malignancy 1 . At metastatic sites, a distinct population of metastasis-associated macrophages promotes the extravasation, seeding and persistent growth of tumour cells 2 . Here we define the origin of these macrophages by showing that Gr1-positive inflammatory monocytes are preferentially recruited to pulmonary metastases but not to primary mammary tumours in mice. This process also occurs for human inflammatory monocytes in pulmonary metastases of human breast cancer cells. The recruitment of these inflammatory monocytes, which express CCR2 (the receptor for chemokine CCL2), as well as the subsequent recruitment of metastasis-associated macrophages and their interaction with metastasizing tumour cells, is dependent on CCL2 synthesized by both the tumour and the stroma. Inhibition of CCL2-CCR2 signalling blocks the recruitment of inflammatory monocytes, inhibits metastasis in vivo and prolongs the survival of tumour-bearing mice. Depletion of tumour-cell-derived CCL2 also inhibits metastatic seeding. Inflammatory monocytes promote the extravasation of tumour cells in a process that requires monocytederived vascular endothelial growth factor. CCL2 expression and macrophage infiltration are correlated with poor prognosis and metastatic disease in human breast cancer [3] [4] [5] [6] . Our data provide the mechanistic link between these two clinical associations and indicate new therapeutic targets for treating metastatic breast cancer.
To understand the origin of macrophages in primary tumours and their metastatic sites, we measured monocyte trafficking. Mouse monocytes were identified by their expression of CD11b and CD115 ( Supplementary Fig. 3a ) and were sorted by fluorescence-activated cell sorting (FACS) into sub-populations of inflammatory monocytes expressing Gr1 and Ly6c and resident monocytes lacking Gr1 and Ly6c (refs 7, 8) ( Supplementary Fig. 3b-d ). Both populations had similar expression of GFP in Csf1r-GFP transgenic mice (Supplementary Fig. 3b ). We adoptively transferred 9-11 10 5 cells of each population into syngeneic FVB mice bearing autochthonous late-stage Polyoma Middle T (PyMT) mammary tumours with spontaneous pulmonary metastases ( Fig. 1a ). Eighteen hours after adoptive transfer, we determined the ratio of recovered GFP-positive inflammatory monocytes ( Supplementary Fig. 3e ) to resident monocytes from the same donor, to measure their relative recruitment. This indicated that there were similar numbers of donor cells in the blood (showing equivalent availability), but that in the primary tumour, resident monocytes were preferentially recruited, whereas in pulmonary metastases, inflammatory monocytes were preferentially recruited, with more than threefold enrichment (Fig. 1b) . Consistent with this, a notable population of endogenous inflammatory monocytes was identified in metastasisbearing lungs but not in normal lungs ( Supplementary Fig. 4a ). This preferential recruitment of inflammatory monocytes in the lung was not observed in 7-week-old PyMT mice bearing pre-metastatic mammary tumours ( Supplementary Fig. 4b ). In experimentally induced pulmonary foci of intravenously injected Met-1 cells (a PyMT-induced mouse mammary tumour cell line) 12 , inflammatory monocytes were also preferentially recruited ( Supplementary Fig. 4c ). GFP-labelled cells were readily detectable in pulmonary metastases at least 5 d after transfer (data not shown) and within 2 d, a significant portion of them had differentiated into F4/80 1 CD11b 1 Gr1 2 metastasis-associated macrophages (MAMs) 2 that are not seen in normal lungs (Supplementary Fig. 4d ). To test whether inflammatory monocytes were recruited early in the metastasis process, we transferred monocyte populations monocytes through CCL2. a, Schematic for the adoptive transfer of monocytes into PyMT-tumour-bearing mice with pulmonary metastases. i.v., intravenous. b, Ratios of inflammatory monocytes (IM) to resident monocytes (RM) in different tissues of recipient mice bearing PyMT tumours and metastases. n 5 6; ***, P , 0.0001. c, Ratios of inflammatory monocytes to resident monocytes in control lungs and in lungs with Met-1 cells intravenously injected 7 h before measurement. n 5 4; **, P 5 0.0039. d, Relative numbers of donor inflammatory monocytes recruited in lungs challenged with Met-1 cells for 7 h, with control or anti-mouse CCL2 antibody treatment. n 5 3; *, P 5 0.045. e, Ratios of adoptively transferred CD14 1 CD16 2 and CD14 low CD16 1 human monocytes recruited into the lungs of normal mice (open bars) and of mice challenged with 4173 cells that contain metastases (Mets: solid bars) for 7 h. n 5 5; **, P 5 0.0163. All bars show mean 1 s.e.m. f, Numbers of adoptively transferred human CD14 1 CD16 2 monocytes that migrated into different tissues of mice challenged with 4173 cells via intravenous injection, with control or anti-mouse CCL2 antibody treatment. Each line connects data from the same donor. n 5 5; *, P 5 0.016. 7 h after intravenous injection of Met-1 cells, a time point before significant interaction between the tumour and macrophages, and before extravasation of tumour cells 2 . Compared to control lungs, the recruitment of inflammatory monocytes to tumour-cell-challenged lungs increased markedly, with the ratio of inflammatory monocytes to resident monocytes increasing more than fivefold ( Fig. 1c ). However, this preferential recruitment of inflammatory monocytes was not observed after intravenous injection with PBS or latex beads, as controls for injection and particle lodgement, respectively ( Supplementary Fig.  4e and data not shown). Consistent with this early recruitment of inflammatory monocytes, MAMs expressing high levels of CCR2 were preferentially recruited to lungs 36 h after tumour-cell inoculation 2 . However, B cells and T cells, including Foxp3 1 regulatory T (T reg ) cells, were not differentially recruited at this time ( Supplementary Fig. 5a -c and data not shown). These data indicate that MAMs are derived from inflammatory monocytes that are specifically recruited early in the process of pulmonary metastasis, before other immune cells.
Distinct chemokine signals recruit inflammatory and resident monocytes 7 , with inflammatory monocytes responding to CCL2 (refs 10, 11). Lung metastases of PyMT tumours express CCL2 homogeneously, in contrast to its heterogeneous expression in primary tumours (Supplementary Fig. 6a-d ), and inflammatory monocytes have high levels of CCR2 expression, whereas resident monocytes do not (Supplementary Fig. 6e ). The neutralization of CCL2 using a CCL2-specific antibody 13 markedly inhibited both the recruitment of inflammatory monocytes to lungs challenged with metastatic tumour cells ( Fig. 1d ) and the increase in the number of MAMs at the metastatic site (Supplementary Fig. 4f ). Other CCR2-expressing leukocytes (a sub-population of T cells) and also T reg cells were unaffected by anti-CCL2 antibody treatment in this model ( Supplementary Fig. 5d ). Furthermore, the preferential recruitment of inflammatory monocytes to the tumour-cellchallenged lung was completely abrogated during adoptive transfer of monocytes sorted from Ccr2-null mice ( Supplementary Fig. 6f ).
The pattern of human monocyte recruitment to tumours in vivo is unknown. To investigate this, human CD14 1 CD16 2 inflammatory monocytes and CD14 low CD16 1 resident monocytes 9 were sorted from enriched CD14 1 cells from the peripheral blood of healthy donors ( Supplementary Fig. 7a ). 10 5 cells of each population were adoptively transferred into pairs of nude mice supplemented with recombinant human colony-stimulating factor 1 (CSF1), which is essential for the survival of monocytes and macrophages ( Supplementary Fig. 7e ). Human monocytes were quantified 18 h after adoptive transfer, using FACS analysis with an antibody against human CD45 ( Supplementary  Fig. 7b ). In normal mice, after adoptive transfer of monocytes from the same donor, there were comparable numbers of human inflammatory monocytes and resident monocytes in the circulation and also recruited to the lung, but about twice the numbers of inflammatory monocytes compared to resident monocytes in the spleen (Fig. 1e , open bars). In mice given an intravenous injection of human MDA-MB-231-derived metastatic 4173 breast cancer cells 14 7 h before monocyte transfer, the ratio of the two monocyte populations in blood and spleen was similar to that in normal mice, but the ratio of inflammatory monocytes to resident monocytes in the lungs increased more than sixfold ( Fig. 1e ). In established pulmonary metastases derived from orthotopically injected 4173 cells, inflammatory monocytes were also preferentially recruited, with a ratio fivefold higher than that in normal lungs ( Supplementary Fig. 7d ). Mouse inflammatory monocytes were also preferentially recruited to lungs challenged with 4173 cells (data not shown). Human inflammatory monocytes express CCR2, whereas resident monocytes express minimal levels of this receptor ( Supplementary Fig. 7c ). The neutralization of host CCL2 with an antibody against mouse CCL2 markedly reduced the recruitment of human inflammatory monocytes into lungs challenged with 4173 cells, without any change in the circulation or spleen (Fig. 1f ). Treatment with an antibody specific to human CCL2 (ref. 15 ) also inhibited inflammatory monocyte recruitment ( Supplementary Fig.  7f ), indicating the importance of CCL2 from both the tumour and the target organ. This shows that human inflammatory monocytes respond to the same CCL2-CCR2 signalling as mouse cells for their specific recruitment during pulmonary metastasis.
To test the effect on metastatic potential of blocking the recruitment of inflammatory monocytes, we performed experimental metastasis assays with Met-1 cells in mice treated with anti-mouse CCL2 or with a control antibody shortly before the tumour-cell injection. Anti-CCL2 treatment reduced the total metastasis burden, owing to a markedly reduced number of metastasis nodules ( Fig. 2a, b ). An antibody specific to mouse CCL12, another ligand of mouse CCR2, had no effect on the metastasis of Met-1 cells ( Supplementary Fig. 8 ). This indicates that the specific CCL2-mediated recruitment of inflammatory monocytes is critical for the pulmonary seeding of tumour cells.
Extravasation is a critical step for the metastatic seeding of tumour cells in the lung 2 . We used an intact-lung imaging system 16 to test the role of CCL2-recruited inflammatory monocytes in tumour-cell extravasation. Csf1r-GFP transgenic mice were injected intravenously with cyan fluorescent protein (CFP)-expressing Met-1 cells and analysed after 24 h. Quantification of three-dimensional reconstructed confocal images (Fig. 2c, d and Supplementary Movies 1 and 2) showed that the number of macrophages interacting directly with tumour cells was significantly reduced by anti-mouse CCL2 neutralizing antibody, compared with control antibody ( Fig. 2e ). Notably, tumour-cell extravasation was delayed and less efficient after the blocking of inflammatory monocytes (Fig. 2f ). Tumour-cell extravasation involves crosstalk between tumour cells, endothelial cells, basement membrane and macrophages. In an in vitro trans-endothelial migration assay ( Supplementary Fig. 9a ) 17 , the trans-endothelial migration of tumour cells was enhanced about fivefold by mouse bone-marrow-derived macrophages (BMDMs) located on the basolateral side of the endothelial monolayer. This effect was blocked by anti-mouse-CCL2 neutralizing antibody, but not by control antibody ( Supplementary Fig. 9b ). Tumour cells, BMDMs and endothelial cells all express CCL2, whereas only the macrophages express CCR2 ( Supplementary Fig. 9c ), indicating that only macrophages respond to the CCL2 chemokine signalling. In confirmation of this, macrophages from Ccr2-null mice were not capable of promoting trans-endothelial migration of tumour cells ( Supplementary Fig. 9d ). Notably, FACS-sorted inflammatory monocytes, but not resident monocytes, markedly promoted tumourcell trans-endothelial migration and this was also inhibited by anti-mouse-CCL2 neutralizing antibody ( Fig. 2g, h) .
Total blockade of CCL2 (both mouse and human) inhibited spontaneous lung metastasis of orthotopically injected MDA-MB-231 cells (Fig. 3a ). Ligands secreted by both the tumour cells and the host contributed to metastatic efficiency, because both anti-human and antimouse antibodies markedly inhibited the experimental metastasis of 4173 cells (Fig. 3b ) without affecting tumour-cell proliferation in vitro (data not shown). This conclusion was also confirmed by knocking down CCL2 using small interfering RNAs in 4173 cells: this markedly reduced lung colonization in experimental metastasis assays (Supplementary Fig. 10e , f). Consistent with this, a similar Ccl2-knockdown in Met-1 cells did not affect tumour-cell proliferation in vitro, but markedly inhibited the metastastic efficiency of the cells ( Supplementary Fig.  10a -c). Trans-endothelial migration of 4173 cells in vitro was also promoted by human inflammatory monocytes and inhibited by neutralizing either human or mouse CCL2 with specific antibodies ( Fig. 3c-e ). These data indicate that CCL2 secreted by both the tumour cell and the target organ promotes tumour-cell extravasation and metastatic seeding via the recruitment of inflammatory monocytes. Consistent with the role of CCL2 synthesized by the microenvironment in the lung, bone metastases of MDA-MB-231 cells also recruit inflammatory monocytes and the inhibition of CCL2 inhibits metastatic progression. In contrast, liver metastases of Met-1 cells did not recruit inflammatory monocytes and CCL2 inhibition did not reduce metastasis (data not shown). Furthermore, CCL2 blockade 2 d after intravenous injection of MDA-MB-231 cells reduced the tumour burden in the lung and prolonged the LETTER RESEARCH survival of mice, indicating the importance of continuous recruitment of inflammatory monocytes and their differentiation into MAMs for persistent metastatic growth (Fig. 3f, g) .
To determine a mechanism for the effects of inflammatory monocytes on tumour-cell extravasation, we analysed the transcriptomes of resident and inflammatory monocytes 18 . Among the differentially regulated genes, vascular endothelial growth factor A (Vegfa) was highly expressed by inflammatory monocytes, a fact that we verified experimentally ( Supplementary Fig. 11a ). To ablate Vegfa conditionally in myeloid cells to test its role in the metastatic process, we generated a transgenic mouse expressing a tamoxifen-inducible Mer-iCre fusion protein driven by the Csf1r promoter, crossed with Vegfa flox/flox mice 19 . Inducible ablation of Vegfa was achieved in cultured BMDMs treated with 4-hydroxytamoxifen ( Fig. 4a ) and these Vegfa-null BMDMs were unable to promote the trans-endothelial migration of tumour cells and did not enhance permeability of the endothelial monolayer, a process importantformetastasis 20 ,whencomparedtocontrolBMDMs (Fig.4b,c) .In vivo injection of tamoxifen specifically ablated Vegfa in monocytes, without ablation in other circulating immune cells (Fig. 4d ). This monocyte-specific depletion of VEGFA markedly inhibited the potential for experimental RESEARCH LETTER metastasis of Met-1 cells and reduced their seeding efficiency ( Fig. 4e and Supplementary Fig. 11b ). Adoptive transfer experiments indicated that Vegfa-null inflammatory monocytes infiltrate Met-1 lung metastases at a comparable level to Vegfa flox inflammatory monocytes, showing that VEGFA is not required for the recruitment of these cells ( Supplementary Fig. 11c ). Notably, co-injection of Met-1 cells and wild-type inflammatory monocytes into inducible macrophage-Vegfaknockout mice restored the metastatic potential of tumour cells (Fig. 4f) .
These experiments indicate that CCL2 synthesized by metastatic tumour cells and by the target-site tissue stroma is critical for the recruitment of a sub-population of CCR2-expressing monocytes that enhance the subsequent extravasation of the tumour cells. Mechanistically, this occurs at least in part through targeted delivery of molecules such as VEGFA that promote extravasation. Inflammatory monocytes are continually recruited by a CCL2-dependent mechanism and differentiate into macrophages that promote the subsequent growth of metastatic cells ( Supplementary Fig. 1 ). These data, together with the clinical association of CCL2 overexpression in human cancers with poor prognosis ( Supplementary Fig. 2) , strongly argue for therapeutic approaches targeted against monocyte recruitment and function.
METHODS SUMMARY
The trafficking of monocytes into primary tumours and their metastases was studied by adoptive transfer of mouse (Ly6c/Gr1 1 or Ly6c/Gr1 2 ) monocytes or human (CD14 1 CD16 1 and CD16 2 ) monocytes, using MMTV-PyMT autochthonous, human and mouse experimental metastasis models and human orthotopic tumour models. Monocytes and macrophages were recovered by enzymatic disaggregation of the tumours, followed by FACS analysis. To investigate mechanisms for monocyte recruitment and the effect of inhibition of this recruitment on metastasis, anti-mouse-CCL2 or anti-human-CCL2 antibodies or Ccr2-null mutant mice were used. To ablate Vegfa expression in monocytes, a myeloid-specific (Csf1r promoter), tamoxifeninducible Cre-expressing strain was crossed with Vegfa flox/flox mice and gene ablation was induced by tamoxifen. The effect of monocyte depletion on tumour-cell extravasation using Met-1, an FVB PyMT-tumour-derived metastatic cell line, was determined using an ex vivo intact-lung imaging system and an in vitro extravasation assay. (MMTV LTR) promoter were provided by W. J. Muller and were bred in-house. FVB (Tg(Csf1r-EGFP)1Jwp) mice have been previously reported to have the whole mononuclear phagocyte system labelled 2 . BL6 Ccr2 tm1Ifc /J mice were purchased from The Jackson Laboratory. The FVB macrophage-specific (Csf1r promoter), tamoxifen-inducible Cre-expressing Tg(Csf1r-Mer-iCre-Mer)1Jwp transgenic mouse strain was generated and crossed with Vegfa flox/flox mice (gift from N. Ferrara). Knockout of Vegfa in myeloid cells was induced by daily subcutaneous injection of 3 mg tamoxifen per mouse for 2 d, before sorting for blood leukocytes or tumour-cell injection. Metastasis assay. Eight-week-old FVB females and six-week-old female nude mice were used for lung experimental-metastasis assays with intravenous injection of 5 3 10 5 Met-1 cells or 10 6 MDA-MB-231-derived LM2 human breast cancer cells, 4173 (ref. 14) , respectively. If not otherwise specified, all animals were killed 2 weeks after intravenous injection of Met-1 cells or 4 weeks after injection of human tumour cells, for optimal metastatic burden. In experimental metastasis assays, antibodies were given at 10 mg kg 21 body weight via intraperitoneal injection 3 h before tumour-cell injection, for single treatments, or twice a week thereafter for prolonged treatments, if not otherwise specified. For paraffin sections, lungs were injected with 1.2 ml of 10% neutral buffered formalin by tracheal cannulation to fix the inner airspaces and inflate the lung lobes. Lungs were excised and fixed in formalin overnight. A precise stereological method 21 with modification was used for quantification of lung metastases. Briefly, paraffin-embedded lungs were systematically sectioned through the entire lung with one 5 mm section taken in every 0.5 mm of lung thickness. All sections were stained with haematoxylin and eosin and images were taken using a Zeiss SV11 microscope with a Retiga 1300 digital camera and analysed using ImageJ 22 . The Mets index is the total volume of metastases normalized to total lung volume and Mets number is the number of metastasis nodules per mm 2 of lung area. Real-time PCR quantification of the burden of human tumour cells was performed as reported previously, using human-specific primers 23 . For spontaneous lung metastasis, 2.5 3 10 6 parental MDA-MB-231 cells or 10 6 derived LM2 4173 tumour cells were orthotopically injected into the inguinal mammary gland of SCID beige or nude mice, respectively. Anti-mouse CCL2 and CCL12 (ref. 23 ) and anti-human CCL2 (ref. 15 ) antibodies neutralize only their respective target molecules and were provided by Ortho Biotech Oncology together with the control antibody. In spontaneous metastasis assays, antibody treatment began on day 3 after tumour-cell intra-mammary-gland injection and continued twice a week thereafter, with each antibody used at 20 mg kg 21 body weight. When each group reached a mean primary-tumour volume of ,1,000 mm 3 , the mice were killed. Lungs were perfused with India ink and placed in Fekete's solution. Lung metastases were counted in a blinded fashion. All in vivo experiments were at least two independent experiments with 3-10 mice for each group. Adoptive transfer. CD115 1 F4/80 1 CD11b 1 Ly6c1/Gr1 1 and Ly6c1/Gr1 2 bonemarrow monocytes were sorted from FVB Csf1r-EGFP mice and adoptively transferred into FVB mice. 10 5 of either cell type were transferred into mice bearing mammary tumours and/or pulmonary metastases. Monocytes were sorted from Ccr2-null mutant mice using the same protocol and were labelled with CellTracker (Invitrogen) following the manufacturer's instructions, before adoptive transfer into nude mice. Fresh human CD14 1 peripheral monocytes were purchased from All Cells LLC. 10 5 CD14 1 CD16 2 and CD14 1 CD16 1 cells were FACS-sorted and intravenously transferred into nude mice supplemented with 2 3 10 6 units of recombinant human CSF1 via subcutaneous injection. In the indicated experiments, specified antibodies were given at 10 mg kg 21 body weight 3 h before adoptive transfer of monocytes. FACS analysis and antibodies. For FACS analysis, lungs or whole mice were perfused thoroughly with cold PBS before cell collection, then lungs were minced on ice and digested with an enzyme mix of Liberase and Dispase (Invitrogen). Blood was drawn by cardiac puncture. Red blood cells were removed using RBC lysis buffer (eBioscience). Cells were blocked using anti-mouse CD16/CD32 antibody (eBioscience) for mouse cells, or 10% goat serum for human cells, before antibody staining. Antibodies against mouse antigens were: CD45 (30-F11), CD11b (M1/70), Gr1 (RB6-8C5), CD115 (AFS98) and Foxp3 (FJK-16 s; all from eBioscience); CD3 (145-2C11) and Ly6c1 (HK1.4; both from Biolegend); CD25 (PC61), CD62L (MEL-14), IL4Ra (mIL4R-M1), CD4 (GK1.5), CD8a (53-6.7) and Ly6G (1A8; all from BD Pharmingen) and F4/80 (Cl:A3-1; AbD Serotec). Antibodies against human antigens were: CD14 (Tük4) and CD16 (3G8; both from Invitrogen), CD45 (HI30; BioLegend) and CCR2 (48607; R&D Systems). FACS analysis was performed on a LSRII cytometer (BD Biosciences) and data were analysed using Flowjo software (TreeStar). Gating of single cells using FSC/ W and SSC/W and exclusion of dead cells with DAPI staining were performed routinely during analysis. Mouse CCL2 was stained using the specific antibody R-17 (Santa Cruz) after a standard immunohistochemistry protocol. Cell culture and in vitro extravasation assay. All cells were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal bovine serum (FBS). The extravasation assay was performed as previously described 17, 24 with modifications. Briefly, 2 3 10 4 endothelial cells (3B-11, ATCC) were plated into the upper chamber of a GFR matrigel invasion chamber (BD Biosciences) in DMEM with 10% (v/v) FBS. A monolayer was formed in 2 d and was verified by microscopy. 10 4 BMDMs or FACS-sorted monocytes were loaded to the basolateral side of the insert and put into a plate-well with DMEM, 10% FBS and 10 4 units ml 21 CSF1 to allow attachment. Vegfa-knockout BMDMs derived from Csf1r-Mer-iCre-Mer:Vegfa flox/flox mice were induced by treating the cells with 1 mM 4-hydroxyltamoxifen for 7 d after isolation of bone marrow. 2 3 10 4 Met-1 cells stained with CellTracker CMRA (Invitrogen) were loaded into the insert with DMEM in 0.5% (v/v) FBS and 10 4 units ml 21 CSF1. CCL2-neutralizing antibody and control antibody were used at 5 ug ml 21 , applied to both sides of the insert. Plates were incubated under normal tissue-culture conditions for 36-48 h before being fixed with 1% (w/v) paraformaldehyde. Tumour-cell trans-endothelial migration was quantified by counting the number of cells that migrated through the insert under a fluorescent microscope (6-10 randomly-selected fields in each insert) and was expressed as cell number per 320 field, if not otherwise specified. The permeability assay was performed by loading 4% (w/v) bovine serum ambumin labelled with Evan's blue into the upper chamber with a pre-formed endothelial monolayer of 3B-11 cells and measuring the absorption of the phenol-red-free medium in the lower chamber at 650 nm after a 30-min incubation in normal culturing conditions. All in vitro experiments were at least three independent experiments with duplicate or triplicate measures. Molecular biology. To knockdown Ccl2 in Met-1 cells, a 97-mer oligo containing a small hairpin RNA (shRNA) that targets the Ccl2 mRNA sequence from nucleotide 166 was cloned into the miR30 context in the retroviral vector P2GM 25 . To knockdown CCL2 in 4173 cells, a 97-mer oligo containing a shRNA targeting the human CCL2 mRNA sequence from nucleotide 255 was cloned into the miR30 context in the same vector. For real-time PCR of mouse Ccl2 expression, primers CCCAATGAGTAGGCTGGAGA and AAAATGGATC CACACCTTGC were used, and for Ccr2, primers CCTGCAAAGACCAGAAG AGG and GTGAGCAGGAAGAGCAGGTC. All real-time PCR was performed on an MJ Research DNA Engine 2 Opticon real-time PCR machine using SYBR master mix (Invitrogen). Primers used were: mouse Ccl2 primers GTTGGC TCAGCCAGATGCA and AGCCTACTCATTGGGATCATCTTG; mouse Ccr2 TTTGTTTTTGCAGATGATTCAA and TGCCATCATAAAGGAGCCAT; mouse Plau ACAGATAAGCGGTCCTCCAG and GCCCCACTACTATGGCTC TG; mouse Vegfa AATGCTTTCTCCGCTCTGAA and GCTTCCTACAGCACA GCAGA; mouse Vegfa exon 3 ACATCTTCAAGCCGTCCTGT and CTGCAT GGTGATGTTGCTCT; human CCL2 AGGTGACTGGGGCATTGAT and GCCTCCAGCATGAAAGTCTC. To verify mouse Vegfa exon 3 knockout, primers that flank this exon, GCTGCACCCACGACAGAAGG and TGAGGTT TGATCCGCATGAT, were used. Ex vivo whole-lung imaging. A well-established intact-lung microscopy technique 16, 26 was applied to observe tumour cells, macrophages and blood vessels in mouse lungs. CFP-expressing Met-1 cells, prepared by retrovirus infection of a CMV-promoter CFP vector, were injected intravenously into the tail vein of each mouse. At the times indicated, mice were anaesthetized and injected with 10 mg AlexaFluor-647-conjugated anti-mouse CD31 antibody (BioLegend). Five minutes later, the mouse was put under artificial ventilation through tracheal cannulation. The lung was cleared of blood by gravity perfusion through the pulmonary artery with artificial medium (Kreb-Ringer bicarbonate buffer with 5% dextran and 10 mmol l 21 glucose (pH 7.4)). The heart-lung preparation was dissected en bloc and placed in a specially designed plexiglass chamber with a port to the artificial cannula. The lung rested on a plexiglass window at the bottom of the chamber with the posterior surface of the lung touching the plexiglass. The lung was ventilated throughout the experiment with 5% CO 2 in medical air and perfused by gravity perfusion except during imaging. Three to five animals were imaged for each time point and 10-20 unrelated fields were imaged for each animal. Images were collected with a Leica TCS SP2 AOBS confocal microscope (Mannheim) with 360 oil-immersion optics. Laser lines at 458 nm, 488 nm and 633 nm for excitation of CFP, GFP and AF647, respectively, were provided by an Ar laser and a HeNe laser. Detection ranges were set to eliminate crosstalk between fluorophores. Three-dimensional reconstruction was performed using Volocity (Improvision Inc.). Statistical analysis. Statistical analysis methods were the standard two-tailed Student's t-test for two data sets and ANOVA followed by Bonferroni/Dunn post RESEARCH LETTER
